RUSH UNIVERSITY MEDICAL CENTER

CG Oncology announced Phase 3 BOND-003 trial data for cretostimogene in high-risk BCG-unresponsive NMIBC, showing 74.5% complete response, median duration exceeding 27 months, 63.5% response at 12 months, and 97.3% free from MIBC progression at 12 months. The treatment had a favorable safety profile with no Grade 3+ adverse events.

CG Oncology announces Phase 3 BOND-003 trial data showing 74.5% of high-risk BCG-unresponsive NMIBC patients achieved complete response with cretostimogene monotherapy, with median duration of response exceeding 27 months. No Grade 3 or greater treatment-related adverse events reported. Cretostimogene received FDA Fast Track and Breakthrough Therapy Designations in December 2023.

New research suggests yoga can help ease emotional stress and depression in women with gynecological, gastrointestinal, or thoracic cancer. A 10-week program combining yoga, mindfulness, and psychotherapy showed reduced anxiety and depression symptoms, particularly beneficial for women of color. Published in 'Integrative Cancer Therapies'.

A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), related to cerebral small vessel disease, may identify dementia risk in clinical trials. The study, led by UT Health San Antonio, found PSMD efficiently processes brain images in multi-site dementia studies and is associated with lower general cognition. PSMD's non-invasive, automated, fast, and reliable nature makes it ideal for clinical trial use.

Augmedics received FDA clearance for its CT-to-fluoroscopy (CT-Fluoro) registration method on the Xvision Spine System, enabling surgeons to navigate using preoperative CT scans and 2D fluoroscopic images, eliminating the need for 3D intraoperative imaging. The first surgical case using this method was completed by Dr. Frank Philips at Rush University Medical Center. Augmedics plans a limited launch at select sites by the end of 2024, with a full U.S. launch scheduled for spring 2025.

Organogenesis Holdings announced positive interim analysis results from its second Phase 3 clinical trial of ReNu for knee osteoarthritis treatment, with the Data Monitoring Committee recommending proceeding without modifications, confirming favorable results and consistent safety profile.

The global cancer-focused genetic testing services market is projected to grow from USD 8,472.70 million in 2024 to USD 19.3 billion by 2034, driven by rising cancer cases, advancements in NGS technology, and declining testing costs. Key markets include the US, UK, India, and China, with significant growth potential. The market is competitive, with established and emerging firms innovating for market share.

Members of the US Pancreatic Disease Study Group include C. Mel Wilcox, Ji Young Bang, Akwi Asombang, Chloe Bennett, Yan Bi, Wojciech Blogowski, James Buxbaum, Wei-Shen Chin, Darwin Conwell, Gregory A. Coté, Timothy B. Gardner, Pramod Garg, Nalini Guda, Robert Hawes, Yasmin G. Hernandez-Barco, Emily Jonica, Prashant Kedia, Thomas Kowalski, Vivek Kumbhari, Linda Lee, Jorge Machicado, Desiree Morgan, Thiruvengadam Muniraj, Udayakumar Navaneethan, Veeral Oza, Swati Pawa, Rajesh Puri, Amit Rastogi, D. Nageshwar Reddy, Monica Saumoy, Mandeep Sawhney, Santhi Swaroop Vege, Rupjyoti Talukdar, Paul Tarnasky, Felix Tellez-Avila, Shyam Thakkar, Nikhil Thiruvengadam, Elaina Vivian, Irving Waxman, Field F. Willingham, Shyam Varadarajulu.

The Woman’s Board of RUSH University Medical Center’s Fall Benefit, themed around the 1893 World’s Fair, featured Gilded Age decor, a wine-delivering bicycle, and a silent auction inspired by Fair innovations. The event aimed to raise funds for education, research, and community service programs, emphasizing RUSH’s mission to transform healthcare. Highlights included a performance by mentalist Sidney Friedman and a dance party with Chicago’s True Blue Band.

Researchers at Rush found a significant connection between gut microbiome and lumbar degenerative spondylolisthesis, identifying specific pro-inflammatory bacteria associated with the condition. This discovery could lead to more targeted treatments for back pain, focusing on gut health.